Why the study?
Do angiotensin II receptor blockers prevent the progression of renal disease in patients with type 2 diabetes?
Population
Patients with type 2 diabetes and nephropathy
Comparison
Angiotensin II receptor blockers such as… vs Placebo or amlodipine
Design
Review
Authors
Loading...
Supports ARB renoprotection in type 2 diabetes; leaves open optimal combinations and real-world durability beyond trial populations.
Do angiotensin II receptor blockers prevent the progression of renal disease in patients with type 2 diabetes?
ARBs effectively slow the progression of nephropathy in patients with type 2 diabetes, independent of their blood pressure-lowering effects.
Edmund J. Lewis (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: